NxStage Celebrates Fifth Annual National Home Hemodialysis Day
NxStage Celebrates Fifth Annual National Home Hemodialysis Day
Company lights Boston's Zakim Bridge and boosts educational awareness efforts on the benefits of home hemodialysis and more frequent therapy.
LAWRENCE, Mass., March 15, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), the manufacturer of the NxStage® System One(TM) home hemodialysis system, is celebrating the fifth annual Home Hemodialysis (HHD) Day on March 15, 2018. Annually observed during National Kidney Month, this initiative focuses on raising awareness of home hemodialysis and more frequent therapy as a viable treatment option for patients requiring dialysis. Boston's iconic Zakim Bridge will be cast in green light on the evening of March 15th to commemorate HHD Day.
"We are proud to continue this tradition of generating awareness of home hemodialysis for the fifth consecutive year," said Joseph Turk, President of NxStage. "Home hemodialysis is an important therapy option for patients suffering with kidney disease. It allows patients to have greater control over their treatment and schedule. And the home is the most practical setting for individualized care and innovative treatment options, such as more frequent hemodialysis, which have been shown to have significant clinical benefits. More frequent hemodialysis is associated with: 13% lower risk of death compared to traditional in-center hemodialysis,(1) 11% reduction in left ventricular hypertrophy, reducing stress on the heart,(2,3) and an 87% improvement in recovery time after treatment.(4 )We hope this HHD Day will help more kidney patients reclaim their lives by talking with their doctors about home hemodialysis and more frequent home hemodialysis."
NxStage is also requesting that patients and their care partners share their stories on social media and update their Facebook profile picture frame to show their support of home hemodialysis.
For more information about HHD Day or NxStage products and services, please visit www.facebook.com/NxStage or www.nxstage.com.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis, home nocturnal hemodialysis and solo home hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners (or for patients prescribed to receive solo dialysis, alone), where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. NxStage also has established a small number of dialysis clinics. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent hemodialysis using the NxStage System One. Additionally, the reported benefits of home and/or more frequent hemodialysis may not be experienced by all patients.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2017. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
References:
1. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. J Am Soc Nephrol. 2012;33(5):895-904.
2. FHN Trial Group. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-2300.
3. Culleton BF, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759-2767.
4. Jaber BL, Lee Y, Collins AJ, et al. Effect of daily hemodialysis on depressive symptoms and post dialysis recover time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. Am J Kidney Dis. 2010;56(3):531-539.
View original content with multimedia:http://www.prnewswire.com/news-releases/nxstage-celebrates-fifth-annual-national-home-hemodialysis-day-300614386.html
SOURCE NxStage Medical, Inc.
